qXR-CTR vs Tempus ECG-AF
AI Verdict
Choose qXR-CTR if…
Choose qXR-CTR if your primary need is an automated, AI-powered solution for rapidly assessing heart size and potential heart failure risk directly from chest X-ray images. This tool is ideal for radiology and cardiology departments seeking to streamline the measurement of cardiothoracic ratio and enhance initial diagnostic screening.
View qXR-CTR →Choose Tempus ECG-AF if…
Choose Tempus ECG-AF if your goal is to proactively identify older patients (65+) at elevated risk of developing new-onset atrial fibrillation within the next year, using standard 12-lead ECG recordings. This is particularly useful for internal medicine and geriatrics practices aiming to implement preventative strategies and earlier follow-up for high-risk individuals.
View Tempus ECG-AF →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | qXR-CTR | Tempus ECG-AF |
|---|---|---|
| Pricing | Unknown | Contact vendor |
| Deployment | Can be deployed on cloud or on-premise. The Qure.ai app receives DICOM studies via DICOM network protocol from medical systems (PACS/Modality) or can import DICOM from the local system. The received DICOM study is processed in Qure's cloud server, and AI-processed reports are displayed on the app. | Software solution, integrated into healthcare facility systems with advanced cardiology algorithms. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Cleared AI-estimated | Yes AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
qXR-CTRTool A (qXR-CTR) offers a more direct user experience through its Qure.ai App, providing visual overlays on X-rays and structured reports, and integrating seamlessly into existing radiology workflows. In contrast, Tool B (Tempus ECG-AF) explicitly states it does not have a dedicated user interface, relying on API and file exchange for integration, which implies a less direct interaction for the end-user.
Clinical Value
Tempus ECG-AFTool B (Tempus ECG-AF) offers a more proactive and potentially impactful clinical intervention by predicting the 12-month risk of new-onset atrial fibrillation in a specific patient population, supported by a large training dataset and a 95% negative predictive value. While Tool A automates CTR measurement for heart failure risk, Tool B's predictive capability for a critical, often asymptomatic condition like AF represents a more advanced clinical utility.
Pricing & Value
Tempus ECG-AFTool B (Tempus ECG-AF) clearly demonstrates superior pricing and value due to the explicit mention of CMS reimbursement and a specific Medicare rate of $128.90, effective January 1, 2025. This transparency and established reimbursement pathway significantly de-risk adoption for healthcare providers. Tool A's pricing is not publicly disclosed, creating uncertainty for potential adopters.
Enterprise Readiness
qXR-CTRBoth tools are FDA-cleared, HIPAA compliant, and offer BAAs, demonstrating fundamental enterprise readiness. However, Tool A (qXR-CTR) offers more explicit deployment flexibility with 'Cloud, on-premise, hybrid' options and a broader list of supported data standards (DICOM, HL7 v2, FHIR, SNOMED CT, ICD-10), giving it a slight edge in adaptability for diverse enterprise environments.
Innovation
Tempus ECG-AFTool B (Tempus ECG-AF) exhibits greater innovation by being the first FDA-cleared AI algorithm to predict the *future risk* of atrial fibrillation within a specific timeframe from ECGs. While Tool A automates a standard measurement, Tool B's predictive capability for a critical, often asymptomatic condition represents a more advanced and novel application of AI in precision medicine.
Support & Docs
qXR-CTRTool A (qXR-CTR) explicitly mentions a 'Qure.ai App User's Manual' and a 'Documentation' section on its website, detailing installation, features, and configuration with medical systems. Tool B (Tempus ECG-AF) provides contact information for a support team and mentions a 'Document Library.' While both offer support, Tool A's more specific mention of user manuals for its application and integration gives it a slight advantage in documented support resources.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | qXR-CTR | Tempus ECG-AF |
|---|---|---|
| Name | qXR-CTR | Tempus ECG-AF |
| Company | Qure.ai Technologies | Tempus AI, Inc. |
| Description | AI-powered software that automates the measurement of the cardiothoracic ratio (CTR) from chest X-ray images, aiding in the assessment of heart size and potential heart failure risk. | FDA-cleared AI-based algorithm that analyzes 12-lead ECG recordings to identify patients aged 65 or older at increased risk of developing atrial fibrillation/flutter (AF) within the next 12 months, supporting earlier identification and follow-up. |
| Categories | Cardiology AI, Radiology & Imaging AI | Cardiology AI |
Videos
Demos, reviews, and walkthroughs featuring qXR-CTR and Tempus ECG-AF.